Multiple Phase 3 clinical trials in human subjects show sustained weight loss averaging 15-22% of body weight at higher doses, along with major HbA1c reductions, improved glycemic control, visceral fat reduction, and better lipid profiles
Olly stands out for being NSF Certified, an independent organization that tests supplements to ensure safety and quality
Some individuals report that fat loss becomes more apparent in specific regions, particularly abdominal adipose tissue, consistent with preclinical data showing preferential visceral fat reduction
Scaling is a huge challenge
Thyroid disorders, including Hashimotos thyroiditis and hypothyroidism, are common in people with metabolic diseases like diabetes and obesity
PlexusDx recommends discussing your clinical situation with a qualified provider to ensure your chosen pathway aligns with your metabolic profile, medical history, and treatment timeline